Researchers: More Evidence Needed For TAVR in Young Patients
from Cardiovascular Business
Researchers from Weill Cornell Medicine in New York are worried the extension of transcatheter aortic valve replacement (TAVR) to younger, intermediate-risk patients is outpacing clinical evidence. Bioprosthetic valves may not hold up for the duration of younger patients’ lifetimes, they said, potentially leading to risky reoperations.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063